Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02428660 · ClinicalTrials.gov registry record · NA
Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM
A NA study of Drug Metabolism, Poor, CYP2D6-Related and Drug Metabolism, Poor, CYP2C19-Related, sponsored by Genelex Corporation.
- Completed
- Registry status
- NA
- Development phase
- 341
- Enrollment target
- 1
- Study location
NCT02428660 is a NA study of Drug Metabolism, Poor, CYP2D6-Related and Drug Metabolism, Poor, CYP2C19-Related that has completed, run by Genelex Corporation. The registered enrollment target is 341 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02428660, a NA study of Drug Metabolism, Poor, CYP2D6-Related and Drug Metabolism, Poor, CYP2C19-Related, has completed, sponsored by Genelex Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 341 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized controlled trial will evaluate whether the use of pharmacogenetic testing through a Medication Therapy Management (MTM) program has a beneficial impact on drug therapy problems. More specifically, cytochrome DNA testing, which provides information with regards to participant specific metabolism of medications, will be used in the evaluation of participant medication regimens. The overall aim of the project is to evaluate if the addition of genetic CYP testing to a standardized MTM Program provides increased clinical value. To answer this question, the investigators will look at the drug therapy problems (DTPs) identified by the genetic test compared to those DTPs discovered without the test.
Conditions Studied
Interventions
- OTHER MTM
- GENETIC Pharmacogenetic testing
- OTHER Software-based drug & gene interaction risk analysis
Study Locations (1)
Utah
- VRx Pharmacy Services - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02428660
The ClinicalTrials.gov registry entry for NCT02428660 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genelex Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Drug Metabolism, Poor, CYP2D6-Related appearing as the primary indexed condition, and to 3 interventions - of which MTM is the first listed.
NCT02428660 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT02428660 about?
NCT02428660 is a clinical study titled "Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM". This randomized controlled trial will evaluate whether the use of pharmacogenetic testing through a Medication Therapy Management (MTM) program has a beneficial impact on drug therapy problems. More specifically, cytochrome DNA testing, which provides information with regards to participant specific...
What is the current status of trial NCT02428660?
This trial is currently completed. It is a NA study. The enrollment target is 341 participants. The study started on 2015-02. Estimated completion is 2017-02.
What conditions does trial NCT02428660 study?
This clinical trial studies the following conditions: Drug Metabolism, Poor, CYP2D6-Related, Drug Metabolism, Poor, CYP2C19-Related, CYP2D6 Polymorphism, Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant.
What interventions are being tested in trial NCT02428660?
The interventions under investigation include: MTM (OTHER), Pharmacogenetic testing (GENETIC), Software-based drug & gene interaction risk analysis (OTHER).
Who is sponsoring clinical trial NCT02428660?
This trial is sponsored by Genelex Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02428660 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Metabolism, Poor, CYP2D6-Related
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Drug Metabolism, Poor, CYP2D6-Related
All registered trials for this condition
Drug Metabolism, Poor, CYP2C19-Related
All registered trials for this condition
Utah
All trials with a study site in Utah
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.